A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is:
Response to treatment will be evaluated according to the revised International Working Group
(IWG) categories natural history, hematologic improvement and cytogenetic response1;2. The
primary objective is:
To determine the rate of complete hematologic response and hematologic improvement (according
to IWG 2006 criteria) in CMML patients treated with 5-azacitidine.